<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ectodermal dysplasias</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ectodermal dysplasias</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Ectodermal dysplasias</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Timothy J Fete, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Dorothy K Grange, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer L Hand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2114402863"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The ectodermal dysplasias (EDs) are a heterogeneous group of at least 50 genetic disorders affecting the development of two or more ectodermal derivatives, including hair, teeth, nails, sweat glands, and certain other tissues [<a href="#rid1">1-3</a>]. Other structures derived from the primitive ectoderm involved in EDs may include the mammary glands, adrenal medulla, central nervous system, inner ear, retina, optic lens, pigment cells, and branchial arch cartilages. Advances in molecular genetics and developmental biology have led to the identification of the causative genes and developmental pathways in all the EDs, as reflected in the 2022 classification system (<a class="graphic graphic_table graphicRef142154" href="/d/graphic/142154.html" rel="external">table 1A</a>) [<a href="#rid3">3</a>].</p><p>This topic review will focus on the classic EDs caused by genetic variants affecting the ectodysplasin signal transduction pathway (<em>EDA</em>,<em> EDAR</em>,<em> EDARADD</em>, and <em>IKBKG</em>), <em>GJB6</em>, and <em>WNT10A</em>. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>X-linked hypohidrotic ectodermal dysplasia (XLHED; MIM #305100)</p><p class="bulletIndent1"><span class="glyph">●</span>Ectodermal dysplasia and immunodeficiency 1 (EDAID1; MIM #300291)</p><p class="bulletIndent1"><span class="glyph">●</span>Ectodermal dysplasia 2, Clouston type (ECTD2; MIM #129500)</p><p></p><p>Tumor protein p63-related disorders and focal dermal hypoplasia (Goltz syndrome) are discussed separately. (See  <a class="medical medical_review" href="/d/html/117131.html" rel="external">"Tumor protein p63 (TP63)-related ectodermal dysplasias"</a> and  <a class="medical medical_review" href="/d/html/117132.html" rel="external">"Focal dermal hypoplasia (Goltz syndrome)"</a>.)</p><p class="headingAnchor" id="H589126593"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>Freire-Maia offered the original major classification scheme in 1971, with primary emphasis on involvement of hair, teeth, nails, or eccrine sweat glands [<a href="#rid4">4</a>]. A new classification proposed in 2009 and updated in 2014 provided a comprehensive list of syndromes and their etiologies [<a href="#rid5">5,6</a>]. In 2019, a newer classification system of EDs that incorporated the molecular etiology and the associated molecular pathways was published [<a href="#rid2">2</a>]. This classification system was further updated in 2022 (<a class="graphic graphic_table graphicRef142154 graphicRef142183" href="/d/graphic/142154.html" rel="external">table 1A-B</a>) [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H2579391537"><span class="h1">HYPOHIDROTIC ECTODERMAL DYSPLASIA</span><span class="headingEndMark"> — </span>Hypohidrotic ectodermal dysplasia (HED) is primarily characterized by hypohidrosis (decreased ability to sweat) or anhidrosis (inability to sweat), hypotrichosis (sparse hair), and hypodontia (missing and abnormal teeth). In 50 to 60 percent of cases, HED is inherited as an X-linked disorder (X-linked hypohidrotic ectodermal dysplasia [XLHED, XHED]), with the rest of the cases showing autosomal recessive or autosomal dominant inheritance.</p><p class="headingAnchor" id="H3089022355"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>HED has been reported worldwide. Based on European data, the estimated incidence is 6.7 per 100,000 births [<a href="#rid7">7</a>]. Since the X-linked form is the most common, males are predominantly affected, although female carriers of an X-linked variant can manifest partial symptoms. Males and females are equally affected in the autosomal dominant and recessive forms of HED.</p><p class="headingAnchor" id="H1295561377"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>Most HED cases are X-linked. The rest of the cases are inherited in an autosomal dominant or recessive manner. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>X-linked hypohidrotic ectodermal dysplasia</strong> – XLHED is caused by variants in the <em>EDA</em> gene, encoding the transmembrane protein ectodysplasin, a member of the tumor necrosis factor (TNF)-related ligand family involved in the early epithelial-mesenchymal interaction that regulates ectodermal appendage formation. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autosomal recessive or dominant hypohidrotic ectodermal dysplasia</strong> – Autosomal recessive and dominant forms are due to variants in the ectodysplasin receptor gene <em>EDAR</em> in 10 to 15 percent of cases, <em>EDAR</em>-associated death domain gene <em>EDARADD</em> in 2 to 3 percent, and <em>WNT10A</em> in 15 to 20 percent [<a href="#rid1">1,8</a>]. The <em>WNT</em> gene family includes a group of related genes encoding signaling molecules involved in the differentiation of various cell lineages through the canonical Wnt/beta-catenin signaling pathway. The canonical EDA pathway is illustrated in the figure (<a class="graphic graphic_figure graphicRef117145" href="/d/graphic/117145.html" rel="external">figure 1</a>).</p><p></p><p>In approximately 10 percent of HED cases, the genetic defect is unknown.</p><p class="headingAnchor" id="H509258903"><span class="h2">Clinical manifestations</span></p><p class="headingAnchor" id="H2202966807"><span class="h3">Cutaneous findings</span><span class="headingEndMark"> — </span>Hypotrichosis and hypohidrosis are the two cardinal cutaneous features of HED. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypotrichosis</strong> – Almost all affected individuals have thin, lightly pigmented, and slow-growing scalp hair compared with unaffected siblings (<a class="graphic graphic_picture graphicRef129288 graphicRef80851" href="/d/graphic/129288.html" rel="external">picture 1A-B</a>) [<a href="#rid9">9</a>]. Facial hair, axillary hair, and pubic hair are not affected. Individuals with HED are prone to develop facial milia-like papules [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypohidrosis</strong> – Hypohidrosis is due to the reduced number and abnormal structure and function of eccrine sweat glands. Heat intolerance is virtually universal in affected individuals [<a href="#rid9">9,11</a>]. Hyperthermia due to the individual's inability to cool by sweating may be a life-threatening complication.</p><p></p><p class="bulletIndent1">Newborn infants with HED may have unexplained fevers and are likely to have very dry, peeling skin [<a href="#rid12">12</a>]. In one survey, nearly 60 percent of children with HED had been initially misdiagnosed with eczema [<a href="#rid13">13</a>]. Darkened periorbital skin is also a common finding (<a class="graphic graphic_picture graphicRef117147" href="/d/graphic/117147.html" rel="external">picture 2</a>). Individuals with HED tend to have a lack of dermal ridges. Occasionally, there are absent, hypoplastic, or accessory nipples (<a class="graphic graphic_picture graphicRef117148" href="/d/graphic/117148.html" rel="external">picture 3</a>).</p><p></p><p class="headingAnchor" id="H1140692794"><span class="h3">Extracutaneous manifestations</span></p><p class="headingAnchor" id="H3203738959"><span class="h4">Hypodontia</span><span class="headingEndMark"> — </span>Hypodontia is the third cardinal feature of HED. Children are often first suspected of having HED when eruption of the first tooth is delayed beyond 12 to 15 months of age. The average number of permanent teeth is nine. Central incisors and canines are often conical or peg shaped (<a class="graphic graphic_picture graphicRef66563" href="/d/graphic/66563.html" rel="external">picture 4</a>) [<a href="#rid9">9,14,15</a>]. Alveolar ridges are hypoplastic due to the paucity of teeth. Absence of teeth and underdevelopment of the alveolar ridges lead to midface hypoplasia, a saddle nose deformity, and relative eversion of the lips.</p><p class="headingAnchor" id="H4050316900"><span class="h4">Other eccrine gland abnormalities</span><span class="headingEndMark"> — </span>Abnormalities and decreased numbers of other eccrine glands result in abnormal respiratory mucous (including in the lower airways), hard or sticky ear cerumen, decreased tears, and decreased saliva. Thick, tenacious respiratory mucous can cause nasal obstruction, and affected individuals have an increased risk of developing acute and chronic otitis media, sinusitis, nosebleeds, and pneumonia [<a href="#rid11">11,16,17</a>].</p><p>Individuals with HED have a higher rate of allergic rhinoconjunctivitis and asthma than the general population [<a href="#rid13">13</a>]. Abnormal meibomian glands lead to dry eye symptoms, including superficial, punctate keratitis [<a href="#rid11">11</a>]. A deep, raspy voice is a consequence of decreased saliva and abnormal respiratory mucous.</p><p class="headingAnchor" id="H1927916617"><span class="h4">Low body mass index</span><span class="headingEndMark"> — </span>The height-for-age of patients with HED does not differ significantly from that of the general population, but weight-for-age and body mass index (BMI) tend to be lower in the younger children, with gradual catch-up by early adulthood [<a href="#rid11">11,18</a>]. In infants and children, the cause of low BMI is due to multiple factors, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormalities in mammary gland function in mothers affected by HED and carrier mothers, with subsequent nursing problems in affected infants [<a href="#rid19">19</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Difficulty with swallowing due to decreased saliva</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Difficulty with chewing due to hypodontia</p><p></p><p>Low weight-for-height may be somewhat protective against hyperthermia as these children have a relatively larger surface area-to-weight ratio and relatively more surface area to exchange heat with the environment.</p><p>The cognitive development in children and adolescents with HED is similar to that of the general population [<a href="#rid20">20,21</a>].</p><p class="headingAnchor" id="H3149232459"><span class="h3">Mild hypohidrotic ectodermal dysplasia</span><span class="headingEndMark"> — </span>Milder manifestations of HED can be found in female carriers of XLHED and in males and females with autosomal dominant hypohidrotic ectodermal dysplasia (ADHED) [<a href="#rid1">1</a>]. Females with XLHED may present with mild manifestations of any or all the cardinal features of HED, such as sparseness of hair; patchy alteration of sweat function; and presence of few, small, or missing teeth. Other features include underdeveloped nipples and reduced milk production.</p><p>Individuals with ADHED show similar, milder, and more generalized clinical manifestations than in XLHED yet lack the patchy, mosaic distribution of sweat gland dysfunction seen in some carrier females with XLHED.</p><p class="headingAnchor" id="H2403482013"><span class="h2">Diagnosis</span></p><p class="headingAnchor" id="H4135266360"><span class="h3">Clinical</span><span class="headingEndMark"> — </span>Hypotrichosis, hypohidrosis, and hypodontia are the key clinical features that suggest the diagnosis of HED. Supplementary diagnostic tests include confocal microscopy for sweat gland count, trichogram examination, and skin biopsy.</p><p class="headingAnchor" id="H2389604575"><span class="h3">Supplementary noninvasive tests</span><span class="headingEndMark"> — </span>Noninvasive tests that support the clinical diagnosis of HED include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Confocal microscopy</strong> – Confocal microscopy shows decreased sweat gland density in the palm of individuals with HED [<a href="#rid22">22-24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trichogram examination</strong> – Trichogram examination (light microscopy examination of the proximal ends of shed hairs) identifies variable shaft abnormalities, including reduced thickness, trichorrhexis nodosa (<a class="graphic graphic_picture graphicRef87473" href="/d/graphic/87473.html" rel="external">picture 5</a>), pili torti (<a class="graphic graphic_picture graphicRef87478" href="/d/graphic/87478.html" rel="external">picture 6</a>), fewer terminal hairs, slower growth rate, fewer follicular units, and fewer hairs per unit [<a href="#rid22">22,25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Other noninvasive methods include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Inspection of the meibomian glands of the eyelid (meibography) [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Noninvasive measurement of tear film break-up time [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Evaluation of sweat production by <a class="drug drug_general" data-topicid="9772" href="/d/drug information/9772.html" rel="external">pilocarpine</a> iontophoresis [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Automated facial recognition is a promising noninvasive technology based on the analysis of facial images that may help in clinical diagnosis of XLHED [<a href="#rid29">29</a>].</p><p></p><p class="headingAnchor" id="H1214319718"><span class="h3">Skin biopsy and histopathology</span><span class="headingEndMark"> — </span>Although not routinely performed, a 4 mm punch biopsy of scalp or palmar skin can confirm the diagnosis of HED. The examination of horizontally sectioned biopsies shows rudimentary or absent eccrine glands [<a href="#rid25">25</a>]. Sweat glands are more likely to be absent in scalp than in palmar skin. Apocrine glands may be hypotrophic. In the scalp skin, the density of pilosebaceous units is also reduced.</p><p class="headingAnchor" id="H3536514844"><span class="h3">Molecular diagnosis</span><span class="headingEndMark"> — </span>Molecular testing is available to identify the specific genetic types of HED [<a href="#rid1">1</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Male proband</strong> – In a male proband, the identification of a hemizygous <em>EDA</em> pathogenic variant or biallelic <em>EDAR</em>,<em> EDARADD</em>, or <em>WNT10A</em> pathogenic variants confirms the diagnosis.</p><p></p><p class="bulletIndent1">The identification of a heterozygo<em>us EDAR</em>, <em>EDARADD</em>, or<em> WNT10A</em> pathogenic variant confirms the diagnosis of mild HED in a male proband with mild manifestations of the cardinal features.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Female proband</strong> – In a female proband, the identification of biallelic <em>EDAR</em>,<em> EDARADD</em>, or<em> WNT10A</em> pathogenic variants establishes the diagnosis of classic HED.</p><p></p><p class="bulletIndent1">The identification of a heterozygo<em>us EDAR</em>, <em>EDARADD</em>, or<em> WNT10A</em> pathogenic variant confirms the diagnosis of mild HED in a female proband with mild manifestations of the cardinal features.</p><p></p><p class="bulletIndent1">The identification of a heterozygous <em>EDA </em>pathogenic variant establishes the diagnosis of XLHED carrier status.</p><p></p><p>Serial single-gene testing is appropriate if physical findings are classic and family history is consistent with X-linked inheritance.</p><p class="bulletIndent1"><span class="glyph">●</span>The initial step is sequence analysis of <em>EDA</em>. If no pathogenic variant is found, then deletion/duplication analysis of <em>EDA</em> should be performed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the proband's findings are classic and consistent with autosomal recessive inheritance or mild and consistent with autosomal dominant inheritance, then sequence analysis of <em>EDAR, EDARADD</em>,<em> </em>and<em> WNT10A</em> should be performed, followed by deletion/duplication analysis if no pathogenic variant is found by sequence analysis [<a href="#rid1">1</a>].</p><p></p><p>Multigene panels are available, which include <em>EDA</em>, <em>EDAR</em>, <em>EDARADD</em>, <em>WNT10A</em>, and multiple other genes of interest (<a class="graphic graphic_table graphicRef142154" href="/d/graphic/142154.html" rel="external">table 1A</a>). The genes included in these panels vary by laboratory.</p><p>Exome sequencing and whole genome sequencing are broader methods of molecular diagnostic testing and may be considered depending upon the patient's clinical presentation.</p><p class="headingAnchor" id="H1058670899"><span class="h2">Prenatal diagnosis</span></p><p class="headingAnchor" id="H1147478116"><span class="h3">Ultrasonography</span><span class="headingEndMark"> — </span>Prenatal ultrasonography can include the assessment of the tooth germs and mandible [<a href="#rid30">30,31</a>]. Ultrasonography has been shown to reliably identify fetal tooth germs at 20 to 22 weeks gestation, with individuals with HED having a reduced number of tooth germs (fewer than six tooth buds in either the mandible or maxilla), as well as thin, hypoplastic alveolar bone.</p><p class="headingAnchor" id="H3026887491"><span class="h3">Prenatal genetic testing</span><span class="headingEndMark"> — </span>Prenatal genetic testing for a specific ED in an ongoing pregnancy is available via chorionic villus sampling or amniocentesis if there is a known familial pathogenic variant in <em>EDA</em>, <em>EDAR</em>, <em>EDARADD</em>, or <em>WNT10A</em>. In the absence of a family history of an ED, prenatal testing with a gene panel could be done if there are features of an ED seen by ultrasound, such as missing tooth buds. (See <a class="local">'Ultrasonography'</a> above.)</p><p>Preimplantation genetic testing is also available at the time of in vitro fertilization but only when familial pathogenic variants have been identified.</p><p class="headingAnchor" id="H2692252741"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of HED may be difficult, as there are at least 50 ED syndromes described, many of which have overlapping manifestations (<a class="graphic graphic_table graphicRef142183" href="/d/graphic/142183.html" rel="external">table 1B</a>). In individuals with HED features and recurrent infections, ectodermal dysplasia and immunodeficiency 1 (EDAID1; MIM #300291) and ectodermal dysplasia and immunodeficiency 2 (EDAID2; MIM #612132) should be considered. (See <a class="local">'Ectodermal dysplasia and immunodeficiency'</a> below.)</p><p class="headingAnchor" id="H3080845927"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>The treatment of HED should be individualized based upon the specific characteristics of the individual affected. It requires a multidisciplinary approach that may involve pediatricians; multiple dental specialists (pediatric dentists, orthodontists, prosthodontists, maxillofacial surgeons); geneticists and genetic counselors; dermatologists; plastic surgeons; orthopedic surgeons; otolaryngologists; ophthalmologists; nutritionists; and occupational, physical, and speech therapists.</p><p class="headingAnchor" id="H166529602"><span class="h3">Prevention of hyperthermia and oral function restoration</span><span class="headingEndMark"> — </span>Treatment of HED is primarily directed at preventing hyperthermia and restoring oral function.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypohidrosis and hyperthermia</strong> – Early diagnosis and close monitoring for hyperthermia is critical and possibly life-saving. Preventive measures include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Avoiding hot environments as much as possible</p><p class="bulletIndent2"><span class="glyph">•</span>Using air conditioning in the home, automobiles, and schools</p><p class="bulletIndent2"><span class="glyph">•</span>Using cooling vests and hand-operated cool misters and fans</p><p class="bulletIndent2"><span class="glyph">•</span>Dousing with cold water during athletic events</p><p></p><p class="bulletIndent1">Additional information and suggestions can be found online at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nfed.org%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2FyT8cU2O8GtHdX75aHgrsy4%3D&amp;TOPIC_ID=110146" target="_blank">National Foundation for Ectodermal Dysplasias</a>.</p><p></p><p class="bulletIndent1">The ability to recognize and manage hyperthermia improves with age. By older school age, many children can recognize that they are overheating and ask to move to a cooler environment, especially if an individualized education plan (IEP) is in place to guide teachers. One of the first signs of overheating may be increased redness. A "buddy system," so that friends in school can help notice increased redness and signs of overheating, may also be helpful.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypodontia, abnormal teeth </strong>– Early involvement with a pediatric dentist is essential, and ultimately, team management with a dentist, orthodontist, and prosthodontist is imperative. Early fitting with dentures (as young as two to four years of age) is essential for mastication, speech and language development, nutrition, and self-esteem. Dental procedures are not commonly covered by health insurance in the United States; the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nfed.org%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2FyT8cU2O8GtHdX75aHgrsy4%3D&amp;TOPIC_ID=110146" target="_blank">National Foundation for Ectodermal Dysplasias</a> offers advice for insurance coverage strategies.</p><p></p><p class="headingAnchor" id="H331413070"><span class="h3">Management of other cutaneous and extracutaneous manifestations of HED</span><span class="headingEndMark"> — </span>Other manifestations of hypohidrotic ectodermal dysplasia (HED) that may require specialist care include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypotrichosis </strong>– Gentle hair products should be used for sparse and brittle hair. In one report, topical <a class="drug drug_general" data-topicid="9236" href="/d/drug information/9236.html" rel="external">cetirizine</a> and oral vitamin D supplementation improved hair density in three female children with HED [<a href="#rid32">32</a>]. Topical <a class="drug drug_general" data-topicid="9655" href="/d/drug information/9655.html" rel="external">minoxidil</a> has also been used with favorable effects in a few patients [<a href="#rid33">33,34</a>].</p><p></p><p class="bulletIndent1">Wigs are often used due to sparse scalp hair. A written prescription for "cranial prosthesis" may be helpful for some patients to obtain a wig. In some cases, up to two wigs per year may be covered for growing children.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eczema/dry skin </strong>– Gentle skin cleansers, moisturizers, and topical corticosteroids may be needed for patients with HED who have dry skin or frank eczema. (See  <a class="medical medical_review" href="/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abnormal respiratory mucous</strong> – Close surveillance by a pediatrician; allergist; and ear, nose, and throat (ENT) specialist is needed to manage frequent respiratory infections and increased risk of atopy. Nasal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> rinses beginning at an early age are useful. Environmental smoke and other irritant exposures should be avoided.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nutrition</strong> – Nasal passages should be cleared before meals. Drinking plenty of fluids with meals is helpful. Consultation with a nutritionist may be required for children failing to thrive.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hearing</strong> – Close monitoring of hearing is important. Impaired hearing may result from hard cerumen impactions and chronic otitis media with effusion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Speech and language </strong>– Speech therapy may help with management of complications of hypodontia, dry mouth, and hoarse voice.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dry eyes</strong> – <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">Artificial tears</a> can be used as needed.</p><p></p><p class="headingAnchor" id="H3368706880"><span class="h2">Investigational therapies</span><span class="headingEndMark"> — </span>Fc-EDA, a recombinant fusion protein consisting of the mouse receptor-binding domain of EDA (100 percent conserved between the mouse and human proteins) and the Fc domain of human immunoglobulin G1 (IgG1), is an ectodysplasin-A1 (EDA1) replacement molecule that binds to the EDA1 receptor (EDAR) and activates the signaling pathway for normal ectodermal development. In mouse models of XLHED, Fc-EDA administered intravenously or intra-amniotically to pregnant females resulted in permanent correction of the disease manifestations in the affected offspring [<a href="#rid35">35,36</a>]. Similar results were observed in dog models after postnatal intravenous administration and prenatal intra-amniotic administration of soluble recombinant EDA [<a href="#rid37">37,38</a>].</p><p>A phase 2 clinical trial of Fc-EDA administered within 2 to 14 days of birth to newborn males with XLHED was inconclusive [<a href="#rid39">39</a>]. Because the human sweat glands form between the 20<sup>th</sup> and 30<sup>th</sup> gestational weeks, the postnatal administration of ectodysplasin is unlikely to promote their development.</p><p>In a compassionate use setting, Fc-EDA was subsequently used by intra-amniotic administration for in utero treatment of three male fetuses affected by XLHED [<a href="#rid40">40</a>]. Two of the treated infants (twins with an older affected brother) had a normal sweat duct density on the soles of the feet, had normal pilocarpine-induced sweating at six months of age, and did not experience any hyperthermia episodes during the first five years of life [<a href="#rid41">41</a>].</p><p>Of note, postnatal magnetic resonance imaging (MRI) and radiographic imaging revealed the presence of 10 and 8 tooth germs in the twins, respectively. Similar findings were noted in the third treated infant, although he had a lower pilocarpine-induced sweat production at six months. Subsequently, three other male subjects were treated prenatally with Fc-EDA, with development of functional sweat glands.</p><p>A prospective, open-label, phase 2 trial of prenatal treatment of up to 20 male fetuses affected with XLHED is underway (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04980638&amp;token=nbsXe3i4qfUea5RCPRHtOY5G%2FPzFIESeuM6wIJ4nJiRL9xy2UH%2Ftr8q5nhmG%2Bp6A4awzCDeOIaKlfM5Zc8LAFg%3D%3D&amp;TOPIC_ID=110146" target="_blank">NCT04980638</a>) [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H2285769047"><span class="h2">Genetic counseling</span><span class="headingEndMark"> — </span>Consultation with a clinical geneticist is key for accurate diagnosis, recommendations for specialty assessments, and reproductive counseling. After a diagnostic visit, an updated genetic consultation is recommended prior to childbearing years, so that the affected individual can better understand their own reproductive risks and options.</p><p class="headingAnchor" id="H3010865297"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>With close monitoring to avoid the life-threatening complications of hyperthermia and multidisciplinary management of the clinical manifestations, the prognosis of HED for normal growth, development, and lifespan is excellent.</p><p class="headingAnchor" id="H2413581242"><span class="h1">ECTODERMAL DYSPLASIA AND IMMUNODEFICIENCY</span></p><p class="headingAnchor" id="H77797564"><span class="h2">Ectodermal dysplasia and immunodeficiency 1</span><span class="headingEndMark"> — </span>Ectodermal dysplasia and immunodeficiency 1 (EDAID1; MIM #300291) is an extremely rare form of X-linked hypohidrotic ectodermal dysplasia (XLHED) seen in males due to hypomorphic variants in the gene for IKK-gamma (<em>IKBKG</em>), previously known as <em>NEMO</em> [<a href="#rid43">43</a>]. Patients have clinical features similar to hypohidrotic ectodermal dysplasia (HED), although often milder, in addition to severe, recurrent infections.</p><p class="headingAnchor" id="H535004961"><span class="h3">Pathogenesis</span><span class="headingEndMark"> — </span>EDAID1 is caused by an X-linked pathogenic variant in <em>IKBKG </em>[<a href="#rid44">44</a>]. Incontinentia pigmenti (IP; MIM #308300) is allelic to X-linked EDAID1 and is caused by a different pathogenic variant (usually a deletion) in <em>IKBKG</em>. IP is typically identified only in female children, as it is generally lethal in utero in males due to the absence of the gene product. (See  <a class="medical medical_review" href="/d/html/15513.html" rel="external">"Incontinentia pigmenti"</a>.)</p><p>HED with osteopetrosis and lymphedema is also due to variants in <em>IKBKG</em> [<a href="#rid45">45-47</a>] and is considered to be a subset of EDAID1.</p><p class="headingAnchor" id="H1298646093"><span class="h3">Clinical features</span><span class="headingEndMark"> — </span>Cutaneous and extracutaneous features of EDAID1 are similar to those seen in XLHED but are often milder (see <a class="local">'Clinical manifestations'</a> above). Male children with EDAID1 have rarely been noted to have a vesiculopapular eruption similar to that seen in female children with IP.</p><p>A wide range of immune defects have been described in patients with EDAID1, including natural killer cell dysfunction, hypogammaglobulinemia, and hypergammaglobulinemia M. (See  <a class="medical medical_review" href="/d/html/3951.html" rel="external">"Syndromic immunodeficiencies"</a>.)</p><p>Affected individuals have severe, recurrent infections due to <em>Staphylococcus aureus</em>;<em> Streptococcus pneumonia</em>;<em> Pseudomonas aeruginosa</em>;<em> Mycobacterium </em>spp;<em> </em>and, more rarely, due to <em>Pneumocystis</em>,<em> </em>viruses, or <em>Candida</em>. Infections are often manifested as bronchiectasis, pneumonia, skin infections, osteomyelitis, or meningitis.</p><p>Inflammatory colitis occurs in approximately 20 percent of affected individuals, often with significant failure to thrive. Autoimmune hemolytic anemia occurs occasionally.</p><p class="headingAnchor" id="H2115321839"><span class="h3">Diagnosis</span><span class="headingEndMark"> — </span>EDAID1 should be suspected in male children with clinical features consistent with HED (hypohidrosis, hypodontia, hypotrichosis) and severe, recurrent infections. Extensive evaluation of the immune system should be directed by an immunologist. The diagnosis is confirmed by molecular genetic testing via <em>IKBKG</em> sequencing and deletion/duplication testing. Such testing is offered by several commercial genetic testing laboratories. In addition, sequencing and deletion/duplication testing for <em>NFKBIA</em> is available through single-gene testing and is also included in several immune deficiency gene sequencing panels.</p><p class="headingAnchor" id="H2012868987"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>The management of the manifestations of HED is discussed above (see <a class="local">'Treatment'</a> above). Treatment of immunodeficiency involves <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> replacement; aggressive antibiotic treatment of severe, recurrent infections; and hematopoietic cell transplantation (HCT). (See  <a class="medical medical_review" href="/d/html/3951.html" rel="external">"Syndromic immunodeficiencies"</a>.)</p><p>Allogenic HCT has been shown to cure most clinical immunodeficiency features, although it does not appear to cure colitis [<a href="#rid48">48,49</a>]. In a report on 29 patients with hypomorphic <em>IKBKG</em>/<em>NEMO</em> variants, the global survival rate after HCT among children with HED and immunodeficiency was 74 percent after a median follow-up of 57 months (range 4 to 108 months) [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H1880365964"><span class="h3">Prognosis</span><span class="headingEndMark"> — </span>Prognosis for long-term survival of individuals with EDAID1 and recurrent, severe infections is poor without HCT. Survival ranges from early infancy to late adolescence, with many patients dying in early childhood.</p><p class="headingAnchor" id="H4038906479"><span class="h2">Ectodermal dysplasia and immunodeficiency 2</span><span class="headingEndMark"> — </span>Ectodermal dysplasia and immunodeficiency 2 (EDAID2; MIM #612132) is a rare form of HED with T cell dysfunction due to heterozygous variants in <em>NFKBIA</em> and is inherited in an autosomal dominant fashion [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/d/html/3951.html" rel="external">"Syndromic immunodeficiencies"</a>.)</p><p class="headingAnchor" id="H701362639"><span class="h1">ECTODERMAL DYSPLASIA 2, CLOUSTON TYPE</span><span class="headingEndMark"> — </span>Ectodermal dysplasia 2, Clouston type (ECTD2 [also known as Clouston syndrome]; MIM #129500) is characterized by nail dystrophy, hyperkeratosis of the palms and soles, and abnormal hair [<a href="#rid51">51</a>]. Individuals with ECTD2 are able to sweat and generally have normal teeth.</p><p class="headingAnchor" id="H2159187209"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>The incidence and prevalence of ECTD2 are unknown. The syndrome was originally described in a large French-Canadian family in 1929 [<a href="#rid52">52</a>]. Later reports identified a large French kindred that had migrated to Scotland, Canada, and the northeastern United States. Clouston syndrome has been identified in families from China, Malaysia, Spain, Britain, and Africa.</p><p class="headingAnchor" id="H3783591199"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>ECTD2 is caused by variants in the gene encoding connexin-30, <em>GJB6</em>, on chromosome 13q11-q12.1 [<a href="#rid53">53</a>]. It is inherited in an autosomal dominant fashion, with nearly 100 percent penetrance. A rare form of ECTD2 with deafness is likely a contiguous gene syndrome with deletion of <em>GJB6 </em>and the connexin 26 gene, which is localized to 13q11-q12 [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H3725935213"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Individuals with ECTD2 sweat normally and have normal dentition but with a tendency toward excess caries.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypotrichosis</strong> – In ECTD2, hair is described as fine, brittle, and sparse. Females are more likely to have total scalp alopecia than males, who may have patchy alopecia. Affected children may have sparse, fine hair early on, with progressive thinning to alopecia later. The eyebrows, eyelashes, and axillary and pubic hair are routinely affected and will be sparse or absent (<a class="graphic graphic_picture graphicRef117167" href="/d/graphic/117167.html" rel="external">picture 7</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nail dystrophy</strong> – Fingernails and toenails are described as short, thick, and slow growing (<a class="graphic graphic_picture graphicRef117169" href="/d/graphic/117169.html" rel="external">picture 8</a>). They can be discolored, hypoplastic, or absent. Nails can be cone shaped or triangular. Thickening of distal ends of fingers (clubbing) is also present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Palmoplantar keratoderma</strong> – Affected individuals have palmoplantar hyperkeratosis, with thickening and dyskeratosis of the entire soles and parts of the palms (<a class="graphic graphic_picture graphicRef117170" href="/d/graphic/117170.html" rel="external">picture 9</a>). (See  <a class="medical medical_review" href="/d/html/110147.html" rel="external">"Palmoplantar keratoderma", section on 'Palmoplantar keratoderma associated with ectodermal dysplasia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin hyperpigmentation</strong> – There can be hyperpigmentation of the skin over the knuckles, elbows, axillae, and areolae (<a class="graphic graphic_picture graphicRef117168" href="/d/graphic/117168.html" rel="external">picture 10</a>). Breast development is normal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ocular abnormalities</strong> – Ophthalmologic defects reported in affected individuals include photophobia, strabismus, conjunctivitis, blepharitis, and premature cataracts.</p><p></p><p class="headingAnchor" id="H4227696226"><span class="h2">Pathology</span><span class="headingEndMark"> — </span>Hair from affected individuals is thin, with decreased tensile strength, disorganized fibrillary structure by light microscopy, reduced birefringence in polarized light, and abnormal cysteine and disulfide bonds [<a href="#rid55">55</a>]. There is disorganization of hair fibrils with loss of the cuticular cortex [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H3172661627"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The clinical diagnosis of ECTD2 is based upon the triad of hypotrichosis, nail dystrophy, and hyperkeratosis of the palms and soles. Molecular genetic testing to confirm the diagnosis should be performed via sequence analysis of <em>GJB6</em>.</p><p class="headingAnchor" id="H1556118283"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>ECTD2 must be differentiated from other syndromes that primarily affect the nails and hair (<a class="graphic graphic_table graphicRef142183" href="/d/graphic/142183.html" rel="external">table 1B</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pachyonychia congenita</strong> – Pachyonychia congenita type 1 (MIM #167200) and type 2 (MIM #167210) are characterized by combinations of hypertrophic nail dystrophy, painful palmoplantar keratoderma, blistering, oral leukokeratosis, pilosebaceous cysts, palmoplantar hyperhidrosis, and keratosis on the trunk and extremities [<a href="#rid51">51</a>]. Of note, palmoplantar hyperkeratosis in Clouston syndrome is not painful. (See  <a class="medical medical_review" href="/d/html/15504.html" rel="external">"Pachyonychia congenita"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>KID syndrome</strong> – KID (keratitis-ichthyosis-deafness) syndrome (MIM #148210) is an autosomal dominant disorder caused by heterozygous variants in the <em>GJB2</em> gene, encoding connexin 26, and is characterized by erythrokeratoderma at birth (<a class="graphic graphic_picture graphicRef90662" href="/d/graphic/90662.html" rel="external">picture 11</a>) and sensorineural deafness [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/d/html/15465.html" rel="external">"Overview and classification of the inherited ichthyoses", section on 'KID syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ectodermal dysplasia 5, hair/nail type</strong> – Ectodermal dysplasia 5, hair/nail type (MIM #614927) maps to chromosome 10q24.32-q25.1 and is characterized by dystrophic nails, thin scalp hair, fine eyebrows and eyelashes, and thin body hair [<a href="#rid58">58</a>]. No causative gene has been identified. The inheritance is autosomal recessive.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ectodermal dysplasia 4, pure hair/nail type</strong> – Ectodermal dysplasia 4, pure hair/nail type (MIM #602032) presents with variable to complete alopecia and dystrophic nails [<a href="#rid59">59</a>]. It is caused by pathogenic variants in <em>KRT85</em> and maps to 12q13.13. The inheritance is autosomal recessive.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Darier disease</strong> – Nail dystrophy is present in most patients with Darier disease (MIM #124200) (<a class="graphic graphic_picture graphicRef81865" href="/d/graphic/81865.html" rel="external">picture 12</a>). The presence of warty papules and plaques in a seborrheic distribution suggests the correct diagnosis. (See  <a class="medical medical_review" href="/d/html/15462.html" rel="external">"Darier disease"</a>.)</p><p></p><p class="headingAnchor" id="H3057727203"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Dystrophic nails may be covered with artificial nails for cosmetic purposes. There is a single case report of hypotrichosis treated with topical <a class="drug drug_general" data-topicid="9655" href="/d/drug information/9655.html" rel="external">minoxidil</a> and tretinoin with benefit [<a href="#rid33">33</a>]. Special hair care products may be used to manage dry and sparse hair. Many individuals choose to wear a wig.</p><p>Emollients and keratolytics are useful for palmoplantar hyperkeratosis.</p><p class="headingAnchor" id="H3959662961"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>Individuals affected by ECTD2 have an excellent overall prognosis and life expectancy.</p><p class="headingAnchor" id="H1977022776"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and classification</strong> – The ectodermal dysplasias (EDs) are a heterogeneous group of nearly 50 inherited disorders characterized by anomalies in at least two of the structures derived from the embryonic ectoderm, with at least one involving the skin appendages (hair, nails, sweat glands) or teeth (<a class="graphic graphic_table graphicRef142154 graphicRef142183" href="/d/graphic/142154.html" rel="external">table 1A-B</a>). Other tissues derived from the primitive ectoderm that can be involved in ED syndromes include the mammary gland, adrenal medulla, pituitary gland, inner ear, optic lens, cranial and sensory ganglia and nerves, retina, pineal body, pigment cells, and branchial arch cartilages. (See <a class="local">'Introduction'</a> above and <a class="local">'Classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypohidrotic ectodermal dysplasia</strong> – Hypohidrotic ectodermal dysplasia (HED) is primarily characterized by hypohidrosis or anhidrosis (inability to sweat), hypotrichosis (sparse hair), and hypodontia (missing and abnormal teeth). It is inherited in an X-linked manner (X-linked hypohidrotic ectodermal dysplasia [XLHED]) in 50 to 60 percent of cases. (See <a class="local">'Hypohidrotic ectodermal dysplasia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical manifestations</strong> – Cardinal clinical signs of HED are hypotrichosis, hypohidrosis, and hypodontia (<a class="graphic graphic_picture graphicRef80851" href="/d/graphic/80851.html" rel="external">picture 1B</a> and <a class="graphic graphic_picture graphicRef66563" href="/d/graphic/66563.html" rel="external">picture 4</a>). Abnormalities and decreased numbers of other eccrine glands result in abnormal respiratory mucous (including in the lower airways), hard ear cerumen, decreased tears, and decreased saliva. Milder manifestations of HED can be found in female carriers of XLHED and in males and females with autosomal dominant forms of HED. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnosis</strong> – The clinical diagnosis of HED is based upon the finding of hypotrichosis, hypohidrosis, and hypodontia. The clinical diagnosis can be confirmed by genetic testing. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Molecular diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management</strong> – The management of patients with HED requires a multidisciplinary approach. Treatment is primarily directed at preventing hyperthermia and restoring oral function. Measures to prevent hyperthermia include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Avoiding hot environments as much as possible</p><p class="bulletIndent3"><span class="glyph">-</span>Using air conditioning in the home, automobiles, and schools</p><p class="bulletIndent3"><span class="glyph">-</span>Using cooling vests and hand-operated cool misters and fans</p><p class="bulletIndent3"><span class="glyph">-</span>Dousing with cold water during athletic events</p><p></p><p class="bulletIndent2">The management of hypodontia requires early involvement with a pediatric dentist, orthodontist, and prosthodontist. Additional information and suggestions can be found online at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nfed.org%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2FyT8cU2O8GtHdX75aHgrsy4%3D&amp;TOPIC_ID=110146" target="_blank">National Foundation for Ectodermal Dysplasias</a>. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ectodermal dysplasia and immunodeficiency 1</strong> – Ectodermal dysplasia and immunodeficiency 1 (EDAID1) is a rare form of XLHED associated with a wide range of immune defects. Affected patients present with cutaneous and extracutaneous features and severe, recurrent bacterial infections. Treatment of immunodeficiency involves <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> replacement; aggressive antibiotic treatment of severe, recurrent infections; and hematopoietic cell transplantation (HCT). (See <a class="local">'Ectodermal dysplasia and immunodeficiency 1'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ectodermal dysplasia 2, Clouston type</strong> – Ectodermal dysplasia 2, Clouston type (ECTD2), also known as Clouston syndrome, is characterized by nail dystrophy, hyperkeratosis of the palms and soles, and abnormal hair. Individuals with ECTD2 are able to sweat and generally have normal teeth. (See <a class="local">'Ectodermal dysplasia 2, Clouston type'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Wright JT, Grange DK, Fete M. Hypohidrotic ectodermal dysplasia. In: GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al (Eds), University of Washington, Seattle, 1993.</li><li><a class="nounderline abstract_t">Wright JT, Fete M, Schneider H, et al. Ectodermal dysplasias: Classification and organization by phenotype, genotype and molecular pathway. Am J Med Genet A 2019; 179:442.</a></li><li><a class="nounderline abstract_t">Peschel N, Wright JT, Koster MI, et al. Molecular Pathway-Based Classification of Ectodermal Dysplasias: First Five-Yearly Update. Genes (Basel) 2022; 13.</a></li><li><a class="nounderline abstract_t">Freire-Maia N. Ectodermal dysplasias. Hum Hered 1971; 21:309.</a></li><li><a class="nounderline abstract_t">Visinoni AF, Lisboa-Costa T, Pagnan NA, Chautard-Freire-Maia EA. Ectodermal dysplasias: clinical and molecular review. Am J Med Genet A 2009; 149A:1980.</a></li><li><a class="nounderline abstract_t">Pagnan NA, Visinoni ÁF. Update on ectodermal dysplasias clinical classification. Am J Med Genet A 2014; 164A:2415.</a></li><li class="breakAll">Orphanet Report Series. Prevalence and incidence of rare diseases: Bibliographic data. Number1, January 2022. https://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf (Accessed on August 03, 2023).</li><li><a class="nounderline abstract_t">Cluzeau C, Hadj-Rabia S, Jambou M, et al. Only four genes (EDA1, EDAR, EDARADD, and WNT10A) account for 90% of hypohidrotic/anhidrotic ectodermal dysplasia cases. Hum Mutat 2011; 32:70.</a></li><li><a class="nounderline abstract_t">Anbouba GM, Carmany EP, Natoli JL. The characterization of hypodontia, hypohidrosis, and hypotrichosis associated with X-linked hypohidrotic ectodermal dysplasia: A systematic review. Am J Med Genet A 2020; 182:831.</a></li><li><a class="nounderline abstract_t">Hsu MM, Chao SC, Lu AC. A novel missense mutation (Gln306His) in exon 7 of the ED1 gene causing anhidrotic ectodermal dysplasia with prominent milia-like facial sebaceous papules. Br J Dermatol 2003; 149:443.</a></li><li><a class="nounderline abstract_t">Wohlfart S, Meiller R, Hammersen J, et al. Natural history of X-linked hypohidrotic ectodermal dysplasia: a 5-year follow-up study. Orphanet J Rare Dis 2020; 15:7.</a></li><li><a class="nounderline abstract_t">Gilitwala ZS, Satpute SR. Unexplained Fever in Infancy: Report of a Rare Case of Hypohidrotic Ectodermal Dysplasia in an Infant. Cureus 2023; 15:e39489.</a></li><li><a class="nounderline abstract_t">Mark BJ, Becker BA, Halloran DR, et al. Prevalence of atopic disorders and immunodeficiency in patients with ectodermal dysplasia syndromes. Ann Allergy Asthma Immunol 2012; 108:435.</a></li><li><a class="nounderline abstract_t">Guckes AD, Roberts MW, McCarthy GR. Pattern of permanent teeth present in individuals with ectodermal dysplasia and severe hypodontia suggests treatment with dental implants. Pediatr Dent 1998; 20:278.</a></li><li><a class="nounderline abstract_t">Lexner MO, Bardow A, Hertz JM, et al. Anomalies of tooth formation in hypohidrotic ectodermal dysplasia. Int J Paediatr Dent 2007; 17:10.</a></li><li><a class="nounderline abstract_t">Dietz J, Kaercher T, Schneider AT, et al. Early respiratory and ocular involvement in X-linked hypohidrotic ectodermal dysplasia. Eur J Pediatr 2013; 172:1023.</a></li><li><a class="nounderline abstract_t">Fete T. Respiratory problems in patients with ectodermal dysplasia syndromes. Am J Med Genet A 2014; 164A:2478.</a></li><li><a class="nounderline abstract_t">Motil KJ, Fete TJ, Fraley JK, et al. Growth characteristics of children with ectodermal dysplasia syndromes. Pediatrics 2005; 116:e229.</a></li><li><a class="nounderline abstract_t">Wahlbuhl-Becker M, Faschingbauer F, Beckmann MW, Schneider H. Hypohidrotic Ectodermal Dysplasia: Breastfeeding Complications Due to Impaired Breast Development. Geburtshilfe Frauenheilkd 2017; 77:377.</a></li><li><a class="nounderline abstract_t">Maxim RA, Zinner SH, Matsuo H, et al. Psychoeducational characteristics of children with hypohidrotic ectodermal dysplasia. ScientificWorldJournal 2012; 2012:532371.</a></li><li><a class="nounderline abstract_t">Hadj-Rabia S, Jacob S, Dufresne H, et al. Cognitive profile of school-age children and teenagers with hypohidrotic ectodermal dysplasia (HED). Am J Med Genet A 2014; 164A:2461.</a></li><li><a class="nounderline abstract_t">Jones KB, Goodwin AF, Landan M, et al. Characterization of X-linked hypohidrotic ectodermal dysplasia (XL-HED) hair and sweat gland phenotypes using phototrichogram analysis and live confocal imaging. Am J Med Genet A 2013; 161A:1585.</a></li><li><a class="nounderline abstract_t">Reinholz M, Gauglitz GG, Giehl K, et al. Non-invasive diagnosis of sweat gland dysplasia using optical coherence tomography and reflectance confocal microscopy in a family with anhidrotic ectodermal dysplasia (Christ-Siemens-Touraine syndrome). J Eur Acad Dermatol Venereol 2016; 30:677.</a></li><li><a class="nounderline abstract_t">Burger K, Schneider AT, Wohlfart S, et al. Genotype-phenotype correlation in boys with X-linked hypohidrotic ectodermal dysplasia. Am J Med Genet A 2014; 164A:2424.</a></li><li><a class="nounderline abstract_t">Rouse C, Siegfried E, Breer W, Nahass G. Hair and sweat glands in families with hypohidrotic ectodermal dysplasia: further characterization. Arch Dermatol 2004; 140:850.</a></li><li><a class="nounderline abstract_t">Romero-Caballero MD, Lozano-García I, Caravaca-Alegría A, Gómez-Rivera S. Morphology of the Meibomian gland evaluated using meibography in patients with hypohidrotic ectodermal dysplasia. Arch Soc Esp Oftalmol (Engl Ed) 2019; 94:165.</a></li><li><a class="nounderline abstract_t">Kaercher T, Dietz J, Jacobi C, et al. Diagnosis of X-Linked Hypohidrotic Ectodermal Dysplasia by Meibography and Infrared Thermography of the Eye. Curr Eye Res 2015; 40:884.</a></li><li><a class="nounderline abstract_t">Basu S, Mitra M, Ghosh A. Evaluation of sweat production by pilocarpine iontophoresis: a noninvasive screening tool for hypohidrosis in ectodermal dysplasia. Indian J Clin Biochem 2013; 28:433.</a></li><li><a class="nounderline abstract_t">Hadj-Rabia S, Schneider H, Navarro E, et al. Automatic recognition of the XLHED phenotype from facial images. Am J Med Genet A 2017; 173:2408.</a></li><li><a class="nounderline abstract_t">Wünsche S, Jüngert J, Faschingbauer F, et al. Noninvasive Prenatal Diagnosis of Hypohidrotic Ectodermal Dysplasia by Tooth Germ Sonography. Ultraschall Med 2015; 36:381.</a></li><li><a class="nounderline abstract_t">Hammersen J, Wohlfart S, Goecke TW, et al. Reliability of prenatal detection of X-linked hypohidrotic ectodermal dysplasia by tooth germ sonography. Prenat Diagn 2019; 39:796.</a></li><li><a class="nounderline abstract_t">Rossi A, Miraglia E, Fortuna MC, et al. Topical cetirizine and oral vitamin D: a valid treatment for hypotrichosis caused by ectodermal dysplasia. J Eur Acad Dermatol Venereol 2017; 31:367.</a></li><li><a class="nounderline abstract_t">Melkote S, Dhurat RS, Palav A, Jerajani HR. Alopecia in congenital hidrotic ectodermal dysplasia responding to treatment with a combination of topical minoxidil and tretinoin. Int J Dermatol 2009; 48:184.</a></li><li><a class="nounderline abstract_t">Lee HE, Chang IK, Im M, et al. Topical minoxidil treatment for congenital alopecia in hypohidrotic ectodermal dysplasia. J Am Acad Dermatol 2013; 68:e139.</a></li><li><a class="nounderline abstract_t">Hermes K, Schneider P, Krieg P, et al. Prenatal therapy in developmental disorders: drug targeting via intra-amniotic injection to treat X-linked hypohidrotic ectodermal dysplasia. J Invest Dermatol 2014; 134:2985.</a></li><li><a class="nounderline abstract_t">Gaide O, Schneider P. Permanent correction of an inherited ectodermal dysplasia with recombinant EDA. Nat Med 2003; 9:614.</a></li><li><a class="nounderline abstract_t">Casal ML, Lewis JR, Mauldin EA, et al. Significant correction of disease after postnatal administration of recombinant ectodysplasin A in canine X-linked ectodermal dysplasia. Am J Hum Genet 2007; 81:1050.</a></li><li><a class="nounderline abstract_t">Margolis CA, Schneider P, Huttner K, et al. Prenatal Treatment of X-Linked Hypohidrotic Ectodermal Dysplasia using Recombinant Ectodysplasin in a Canine Model. J Pharmacol Exp Ther 2019; 370:806.</a></li><li><a class="nounderline abstract_t">Huttner K. Future developments in XLHED treatment approaches. Am J Med Genet A 2014; 164A:2433.</a></li><li><a class="nounderline abstract_t">Schneider H, Faschingbauer F, Schuepbach-Mallepell S, et al. Prenatal Correction of X-Linked Hypohidrotic Ectodermal Dysplasia. N Engl J Med 2018; 378:1604.</a></li><li><a class="nounderline abstract_t">Schneider H. Ectodermal dysplasias: New perspectives on the treatment of so far immedicable genetic disorders. Front Genet 2022; 13:1000744.</a></li><li><a class="nounderline abstract_t">Schneider H, Hadj-Rabia S, Faschingbauer F, et al. Protocol for the Phase 2 EDELIFE Trial Investigating the Efficacy and Safety of Intra-Amniotic ER004 Administration to Male Subjects with X-Linked Hypohidrotic Ectodermal Dysplasia. Genes (Basel) 2023; 14.</a></li><li><a class="nounderline abstract_t">Zonana J, Elder ME, Schneider LC, et al. A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). Am J Hum Genet 2000; 67:1555.</a></li><li><a class="nounderline abstract_t">Döffinger R, Smahi A, Bessia C, et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat Genet 2001; 27:277.</a></li><li><a class="nounderline abstract_t">Dupuis-Girod S, Corradini N, Hadj-Rabia S, et al. Osteopetrosis, lymphedema, anhidrotic ectodermal dysplasia, and immunodeficiency in a boy and incontinentia pigmenti in his mother. Pediatrics 2002; 109:e97.</a></li><li><a class="nounderline abstract_t">Carlberg VM, Lofgren SM, Mann JA, et al. Hypohidrotic ectodermal dysplasia, osteopetrosis, lymphedema, and immunodeficiency in an infant with multiple opportunistic infections. Pediatr Dermatol 2014; 31:716.</a></li><li><a class="nounderline abstract_t">Roberts CM, Angus JE, Leach IH, et al. A novel NEMO gene mutation causing osteopetrosis, lymphoedema, hypohidrotic ectodermal dysplasia and immunodeficiency (OL-HED-ID). Eur J Pediatr 2010; 169:1403.</a></li><li><a class="nounderline abstract_t">Pai SY, Levy O, Jabara HH, et al. Allogeneic transplantation successfully corrects immune defects, but not susceptibility to colitis, in a patient with nuclear factor-kappaB essential modulator deficiency. J Allergy Clin Immunol 2008; 122:1113.</a></li><li><a class="nounderline abstract_t">Miot C, Imai K, Imai C, et al. Hematopoietic stem cell transplantation in 29 patients hemizygous for hypomorphic IKBKG/NEMO mutations. Blood 2017; 130:1456.</a></li><li><a class="nounderline abstract_t">Courtois G, Smahi A, Reichenbach J, et al. A hypermorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J Clin Invest 2003; 112:1108.</a></li><li class="breakAll">Mellerio J, Greenblatt D. Hidrotic ectodermal dysplasia 2. In: GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al (Eds), University of Washington, Seattle, 1993.</li><li><a class="nounderline abstract_t">Clouston HR. A Hereditary Ectodermal Dystrophy. Can Med Assoc J 1929; 21:18.</a></li><li><a class="nounderline abstract_t">Lamartine J, Munhoz Essenfelder G, Kibar Z, et al. Mutations in GJB6 cause hidrotic ectodermal dysplasia. Nat Genet 2000; 26:142.</a></li><li><a class="nounderline abstract_t">Kelsell DP, Dunlop J, Stevens HP, et al. Connexin 26 mutations in hereditary non-syndromic sensorineural deafness. Nature 1997; 387:80.</a></li><li><a class="nounderline abstract_t">Reynold JM, Gold MB, Scriver CR. The characterization of hereditary abnormalities of keratin: Clouston's ectodermal dysplasia. Birth Defects Orig Artic Ser 1971; 7:91.</a></li><li><a class="nounderline abstract_t">Escobar V, Goldblatt LI, Bixler D, Weaver D. Clouston syndrome: an ultrastructural study. Clin Genet 1983; 24:140.</a></li><li><a class="nounderline abstract_t">Richard G, Rouan F, Willoughby CE, et al. Missense mutations in GJB2 encoding connexin-26 cause the ectodermal dysplasia keratitis-ichthyosis-deafness syndrome. Am J Hum Genet 2002; 70:1341.</a></li><li><a class="nounderline abstract_t">Rafiq MA, Faiyaz-Ul-Haque M, Ud Din MA, et al. A novel locus of ectodermal dysplasia maps to chromosome 10q24.32-q25.1. J Invest Dermatol 2005; 124:338.</a></li><li><a class="nounderline abstract_t">Naeem M, Wajid M, Lee K, et al. A mutation in the hair matrix and cuticle keratin KRTHB5 gene causes ectodermal dysplasia of hair and nail type. J Med Genet 2006; 43:274.</a></li></ol></div><div id="topicVersionRevision">Topic 110146 Version 6.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Wright JT, Grange DK, Fete M. Hypohidrotic ectodermal dysplasia. In: GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al (Eds), University of Washington, Seattle, 1993.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30703280" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Ectodermal dysplasias: Classification and organization by phenotype, genotype and molecular pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36553593" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Molecular Pathway-Based Classification of Ectodermal Dysplasias: First Five-Yearly Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5139249" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Ectodermal dysplasias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19681154" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Ectodermal dysplasias: clinical and molecular review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25098893" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Update on ectodermal dysplasias clinical classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25098893" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Update on ectodermal dysplasias clinical classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20979233" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Only four genes (EDA1, EDAR, EDARADD, and WNT10A) account for 90% of hypohidrotic/anhidrotic ectodermal dysplasia cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31981414" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The characterization of hypodontia, hypohidrosis, and hypotrichosis associated with X-linked hypohidrotic ectodermal dysplasia: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12932274" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A novel missense mutation (Gln306His) in exon 7 of the ED1 gene causing anhidrotic ectodermal dysplasia with prominent milia-like facial sebaceous papules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31924237" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Natural history of X-linked hypohidrotic ectodermal dysplasia: a 5-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37362526" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Unexplained Fever in Infancy: Report of a Rare Case of Hypohidrotic Ectodermal Dysplasia in an Infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22626597" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prevalence of atopic disorders and immunodeficiency in patients with ectodermal dysplasia syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9783300" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pattern of permanent teeth present in individuals with ectodermal dysplasia and severe hypodontia suggests treatment with dental implants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17181574" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Anomalies of tooth formation in hypohidrotic ectodermal dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23553579" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Early respiratory and ocular involvement in X-linked hypohidrotic ectodermal dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24842607" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Respiratory problems in patients with ectodermal dysplasia syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16061575" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Growth characteristics of children with ectodermal dysplasia syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28553001" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hypohidrotic Ectodermal Dysplasia: Breastfeeding Complications Due to Impaired Breast Development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22536143" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Psychoeducational characteristics of children with hypohidrotic ectodermal dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25159892" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cognitive profile of school-age children and teenagers with hypohidrotic ectodermal dysplasia (HED).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23687000" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Characterization of X-linked hypohidrotic ectodermal dysplasia (XL-HED) hair and sweat gland phenotypes using phototrichogram analysis and live confocal imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25758344" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Non-invasive diagnosis of sweat gland dysplasia using optical coherence tomography and reflectance confocal microscopy in a family with anhidrotic ectodermal dysplasia (Christ-Siemens-Touraine syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24715423" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Genotype-phenotype correlation in boys with X-linked hypohidrotic ectodermal dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15262696" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Hair and sweat glands in families with hypohidrotic ectodermal dysplasia: further characterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30795945" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Morphology of the Meibomian gland evaluated using meibography in patients with hypohidrotic ectodermal dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25310457" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Diagnosis of X-Linked Hypohidrotic Ectodermal Dysplasia by Meibography and Infrared Thermography of the Eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24426251" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Evaluation of sweat production by pilocarpine iontophoresis: a noninvasive screening tool for hypohidrosis in ectodermal dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28691769" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Automatic recognition of the XLHED phenotype from facial images.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25140498" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Noninvasive Prenatal Diagnosis of Hypohidrotic Ectodermal Dysplasia by Tooth Germ Sonography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30394555" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Reliability of prenatal detection of X-linked hypohidrotic ectodermal dysplasia by tooth germ sonography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27504742" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Topical cetirizine and oral vitamin D: a valid treatment for hypotrichosis caused by ectodermal dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19200200" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Alopecia in congenital hidrotic ectodermal dysplasia responding to treatment with a combination of topical minoxidil and tretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23522427" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Topical minoxidil treatment for congenital alopecia in hypohidrotic ectodermal dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24950237" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Prenatal therapy in developmental disorders: drug targeting via intra-amniotic injection to treat X-linked hypohidrotic ectodermal dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12692542" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Permanent correction of an inherited ectodermal dysplasia with recombinant EDA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17924345" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Significant correction of disease after postnatal administration of recombinant ectodysplasin A in canine X-linked ectodermal dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31000577" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Prenatal Treatment of X-Linked Hypohidrotic Ectodermal Dysplasia using Recombinant Ectodysplasin in a Canine Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24678015" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Future developments in XLHED treatment approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29694819" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Prenatal Correction of X-Linked Hypohidrotic Ectodermal Dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36147498" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Ectodermal dysplasias: New perspectives on the treatment of so far immedicable genetic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36672894" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Protocol for the Phase 2 EDELIFE Trial Investigating the Efficacy and Safety of Intra-Amniotic ER004 Administration to Male Subjects with X-Linked Hypohidrotic Ectodermal Dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11047757" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11242109" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12042591" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Osteopetrosis, lymphedema, anhidrotic ectodermal dysplasia, and immunodeficiency in a boy and incontinentia pigmenti in his mother.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23405946" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Hypohidrotic ectodermal dysplasia, osteopetrosis, lymphedema, and immunodeficiency in an infant with multiple opportunistic infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20499091" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A novel NEMO gene mutation causing osteopetrosis, lymphoedema, hypohidrotic ectodermal dysplasia and immunodeficiency (OL-HED-ID).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18851875" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Allogeneic transplantation successfully corrects immune defects, but not susceptibility to colitis, in a patient with nuclear factor-kappaB essential modulator deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28679735" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Hematopoietic stem cell transplantation in 29 patients hemizygous for hypomorphic IKBKG/NEMO mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14523047" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A hypermorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14523047" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A hypermorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20317409" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A Hereditary Ectodermal Dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11017065" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Mutations in GJB6 cause hidrotic ectodermal dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9139825" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Connexin 26 mutations in hereditary non-syndromic sensorineural deafness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5173317" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The characterization of hereditary abnormalities of keratin: Clouston's ectodermal dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6616952" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clouston syndrome: an ultrastructural study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11912510" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Missense mutations in GJB2 encoding connexin-26 cause the ectodermal dysplasia keratitis-ichthyosis-deafness syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15675952" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A novel locus of ectodermal dysplasia maps to chromosome 10q24.32-q25.1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16525032" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A mutation in the hair matrix and cuticle keratin KRTHB5 gene causes ectodermal dysplasia of hair and nail type.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
